A new treatment for vision loss caused by diabetes
A novel PEDF peptide mimetic for diabetic retinopathy
This study is working on a new eye treatment for people with diabetes to help protect their vision from diabetic retinopathy, using a special protein that has shown promise in reducing inflammation and improving eyesight in tests.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Skyran Biologics, INC. NIH-funded |
| Lab location | 1 site (Harrisburg, UNITED STATES) |
| Project ID | NIH-10680606 on NIH RePORTER |
What this research studies
This research focuses on developing a topical treatment for diabetic retinopathy, a major cause of vision loss in people with diabetes. The team has identified a specific protein, Pigment Epithelium-Derived Factor (PEDF), that protects the retina and has created over 40 different versions of a small peptide derived from it. They have tested these peptides in laboratory settings and found that one particular peptide, Spx81-5, shows promise in reducing inflammation and improving vision in diabetic animal models. The goal is to create a safe and effective treatment that can be easily applied to the eye.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetic retinopathy who are experiencing vision problems.
Not a fit: Patients without diabetes or those who do not have diabetic retinopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment for preventing vision loss in diabetic patients.
How similar studies have performed: Previous research has shown that similar approaches using peptide mimetics have been effective in treating other ocular conditions, indicating potential for success in this area.
Where this research is happening
Harrisburg, UNITED STATES
- Skyran Biologics, INC. — Harrisburg, United States (Active)
Researchers
- Principal investigator: Wei, Ji-Ye — Skyran Biologics, INC.
- Study coordinator: Wei, Ji-Ye
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.